Regeneron begins drug testing program for gout patients
Regeneron Pharmaceuticals Inc., a biotech company in Eastview, said that it has started a testing program to evaluate the effectiveness of its Arcalyst drug as a treatment for gout.
Regeneron said that it expected to release preliminary results of the tests in 2010. The testiing program will involve hundreds of patients.
“Nearly one and a half million Americans are treated for gout each year, but significant unmet medical needs persist,” Dr. George D. Yancopoulos, president of Regeneron Research Laboratories, said in a written statement.
Arcalyst, Regeneron’s only marketable drug, was approved last year for treatment of a rare auto-inflammatory condition known as CAPS.